AstraZeneca said it plans to conduct a new global clinical trial to assess the Oxford-AstraZeneca vaccine’s efficacy. The news comes after the company and the university acknowledged a dosing error in trials.
More: In a statement Wednesday, Oxford University said some of the vials used in the trial didn’t have the right concentration of vaccine so some volunteers got a half dose. The university said that it discussed the problem with regulators, and agreed to complete the late-stage trial with two groups.
The manufacturing problem has been corrected, according to the statement.